

Pestivirus N^{Pro} Directly Interacts with Interferon Regulatory Factor 3 Monomer and Dimer

Keerthi Gottipati,^a Luis Marcelo F. Holthausen,^a Nicolas Ruggli,^b Kyung H. Choi^a

Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, Texas, USA^a; The Institute of Virology and Immunology (IVI), Mittelhäusern, Switzerland^b

ABSTRACT

Interferon regulatory factor 3 (IRF3) is a transcription factor involved in the activation of type I alpha/beta interferon (IFN- α/β) in response to viral infection. Upon viral infection, the IRF3 monomer is activated into a phosphorylated dimer, which induces the transcription of interferon genes in the nucleus. Viruses have evolved several ways to target IRF3 in order to subvert the innate immune response. Pestiviruses, such as classical swine fever virus (CSFV), target IRF3 for ubiquitination and subsequent proteasomal degradation. This is mediated by the viral protein N^{Pro} that interacts with IRF3, but the molecular details for this interaction are largely unknown. We used recombinant N^{Pro} and IRF3 proteins and show that N^{Pro} interacts with IRF3 directly without additional proteins and forms a soluble 1:1 complex. The full-length IRF3 but not merely either of the individual domains is required for this interaction. The interaction between N^{Pro} and IRF3 is not dependent on the activation state of IRF3, since N^{Pro} binds to a constitutively active form of IRF3 in the presence of its transcriptional coactivator, CREB-binding protein (CBP). The results indicate that the N^{Pro}-binding site on IRF3 encompasses a region that is unperturbed by the phosphorylation and subsequent activation of IRF3 and thus excludes the dimer interface and CBP-binding site.

IMPORTANCE

The pestivirus N-terminal protease, N^{Pro}, is essential for evading the host's immune system by facilitating the degradation of interferon regulatory factor 3 (IRF3). However, the nature of the N^{Pro} interaction with IRF3, including the IRF3 species (inactive monomer versus activated dimer) that N^{Pro} targets for degradation, is largely unknown. We show that classical swine fever virus N^{Pro} and porcine IRF3 directly interact in solution and that full-length IRF3 is required for interaction with N^{Pro}. Additionally, N^{Pro} interacts with a constitutively active form of IRF3 bound to its transcriptional cofactor, the CREB-binding protein. This is the first study to demonstrate that N^{Pro} is able to bind both inactive IRF3 monomer and activated IRF3 dimer and thus likely targets both IRF3 species for ubiquitination and proteasomal degradation.

The hallmark of the innate immune response against viruses is the activation of type I alpha/beta interferon (IFN- α/β) signaling in immune cells (1, 2). IFN- α/β synthesis is triggered by several of the interferon regulatory factors (IRFs) (3–5). IRF3 is expressed constitutively in various cell types. In uninfected cells, IRF3 exists as an inactive monomer in a latent state in the cytoplasm. Upon viral infection, IRF3 is activated by phosphorylation by cellular kinases, such as TBK-1/I κ B kinase ϵ (IKK ϵ), through engagement of pattern recognition receptors (PRRs) in the immune cells (6). PRRs recognize anomalous non-self motifs called pathogen-associated molecular patterns (PAMPs), such as the double-stranded (dsRNA) intermediates and 5'-triphosphorylated RNA formed during viral RNA replication. Two groups of PRRs activate type I IFN signaling following RNA virus infection. The Toll-like receptors recognize dsRNA in endosomal compartments, and helicases like RIG-1/MDA5 recognize cytosolic dsRNA intermediates (7, 8). Both pathways result in the phosphorylation and activation of IRF3.

IRF3 is an ~50-kDa protein with two functional domains, the N-terminal DNA-binding domain (DBD) and the C-terminal IRF association domain (IAD), also called the regulatory domain (9). The IAD carries the dimerization interface, the autoinhibitory region, and the serine-rich region (10) (Fig. 1A). Phosphorylation of IRF3 occurs at two serine clusters in the serine-rich region. In the proposed model of IRF3 activation, phosphorylation induces a conformational change in the autoinhibitory domain, releasing a

buried hydrophobic surface to enable dimerization of IRF3 (11–13). The activated IRF3 dimer then translocates from the cytoplasm to the nucleus, where the IRF3 dimer binds to the transcriptional coactivator CREB-binding protein (CBP) and subsequently to the DNA promoter to activate transcription of beta interferon genes (14). IRF3 activation is essential for the host to mount innate and adaptive antiviral responses (15).

Pestiviruses, such as bovine viral diarrhea virus (BVDV) and classical swine fever virus (CSFV), have two mechanisms to counter the innate immune responses of dendritic cells (DCs) and macrophages (16). One mechanism involves the glycoprotein E^{rns}. The secreted form of E^{rns} is released into the extracellular space, where a role of E^{rns} for degradation of extracellular viral dsRNA and single-stranded RNA molecules has been postulated (17–19). Interestingly, E^{rns} can enter cells by clathrin-dependent endocytosis and digest viral RNA in endolysosomal compartments via its

Received 25 February 2016 Accepted 6 June 2016

Accepted manuscript posted online 22 June 2016

Citation Gottipati K, Holthausen LMF, Ruggli N, Choi KH. 2016. Pestivirus N^{Pro} directly interacts with interferon regulatory factor 3 monomer and dimer. *J Virol* 90:7740–7747. doi:10.1128/JVI.00318-16.

Editor: M. S. Diamond, Washington University School of Medicine

Address correspondence to Kyung H. Choi, kychoi@utmb.edu.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.




FIG 1 N^{PRO} forms a complex with the full-length IRF3 monomer. (A) Schematic of IRF3 domains. IRF3 consists of the DNA-binding domain (DBD; green), a linker (gray), and the IRF association domain (IAD; yellow). The IAD contains the autoinhibitory region along with the C-terminal phosphorylation sites, sites I and II (blue). Residues in the phosphorylation (P) sites that were mutated to glutamic acid to generate the phosphomimetic mutant IRF3-5E/E are indicated. (B) Gel shift assay of IRF3 in the presence of full-length and Δ 17N N^{PRO}. (Left) IRF3 alone and IRF3 mixed with either full-length N^{PRO} (lane WT [wild type]) or the N-terminal deletion mutant (lane Δ 17N N^{PRO}) were loaded onto native polyacrylamide gels. The gels were spliced, indicated by a space between lanes, to facilitate viewing. N^{PRO}-IRF3 complexes (indicated by † and ‡) were eluted for SDS-PAGE analysis. (Right) SDS-PAGE of the Δ 17N N^{PRO}-IRF3 complex (lane 1) and full-length N^{PRO}-IRF3 complex (lane 4) eluted from native polyacrylamide gels, along with that of purified IRF3 (lanes 2 and 5), Δ 17N N^{PRO} (lane 3), and full-length N^{PRO} (lane 6). (C) (Left) Elution profile from size exclusion chromatography of IRF3 and Δ 17N N^{PRO} protein solution. The absorbance at 280 nm was monitored. mAU, milli-absorbance units. (Right) SDS-PAGE of the fractions from the two peaks. Peak 1 contains both IRF3 and Δ 17N N^{PRO} coeluting from the column. Excess unbound N^{PRO} in the protein mix eluted at a higher volume in peak 2. (D) Sedimentation (sed) velocity profiles of IRF3 alone and the Δ 17N N^{PRO}-IRF3 complex. IRF3 is a monomer with a molecular mass of 42 kDa. The N^{PRO} and IRF3 mixture shows peaks corresponding to free N^{PRO} (~19 kDa) and the bound 1:1 complex of IRF3 and N^{PRO} (~57 kDa). The numbers to the left and right of the SDS-PAGE gels are molecular masses (in kilodaltons).

RNase activity before they can trigger type I IFN induction (20). Importantly, E^{PRO} is very efficient at preventing activation of plasmacytoid dendritic cells (pDCs) in contact with CSFV-infected cells (21). A second layer of protection against the antiviral response is provided by the N-terminal protease (N^{PRO}). The N^{PRO} protein is a leader cysteine autoprotease that cleaves itself from the nascent polyprotein during translation of the viral mRNA (22, 23). The released N^{PRO} suppresses the transcriptional activation of the IFN- α / β genes by interacting with IRF3 and inducing its ubiquitination and proteasome-dependent degradation (24–27). N^{PRO} also interferes with the activity of IRF7 in pDCs, although this interference is probably of minor importance (28). In pigs, N^{PRO} contributes to pathogenicity by interfering with the activation of IFN responses at local replication sites (29). This is, however, not essential for the virus to establish infection, although a CSFV isolate with a complete deletion of the N^{PRO} gene was shown to be attenuated in pigs (30, 31). The protease activity of N^{PRO} is not involved in the degradation of IRF3, since mutation of the catalytic Cys69 had no effect on anti-IFN function (30). An intact zinc-binding site in N^{PRO} (C112-C134-D136-C138) is essential for targeting IRF3 for proteasomal degradation, since mutant CSFV or BVDV strains containing individual mutations in the Zn-binding site were unable to inhibit the interferon response in the host cell (30, 32, 33). Interactions between N^{PRO} and IRF3/IRF7 were demonstrated using coprecipitation and mammalian two-hybrid

assays (25, 26, 28, 32). In particular, mammalian two-hybrid assays in HEK293T cells identified that most of the IRF3 protein, including both the DNA-binding and IRF association domains, is required for N^{PRO}-IRF3 and N^{PRO}-IRF7 interactions (28).

Recent crystal structures of pestivirus N^{PRO} show that N^{PRO} has a unique clam shell-like fold consisting of two domains, a cysteine protease domain and a zinc-binding domain (34, 35). The structure establishes the mechanism of autocatalysis and subsequent autoinhibition of N^{PRO} but provided little clue as to how N^{PRO} binds and mediates IRF3 degradation. Currently, it is not known whether N^{PRO} binds IRF3 directly without any other protein and whether the monomeric or dimeric form of IRF3 or both forms interact with N^{PRO}. In order to explore this, we studied the interactions between purified recombinant CSFV N^{PRO} and porcine IRF3 proteins *in vitro*. N^{PRO} interacts with IRF3 directly without additional proteins and forms a stable 1:1 complex. In addition, N^{PRO} recognizes both the inactive IRF3 monomer and the phosphomimetic IRF3 dimer for binding, thus likely targeting all forms of IRF3 species for proteasomal degradation.

MATERIALS AND METHODS

Construction of porcine IRF3 and CBP₄₈ proteins. The gene coding for porcine IRF3 (GenBank accession number AB116563) was synthesized and cloned into a pJ414 vector that carries the T7 polymerase promoter and ampicillin resistance (pJ414-IRF3; DNA2.0, Menlo Park, CA). All

TABLE 1 Primers used for sequential site-directed mutagenesis to generate the phosphomimetic mutant IRF3-5E/E^a

Protein	Primer	Sequence
IRF3-1E	S394E (forward)	CCGTGGATCTGCACATCGAGAATAGCCATCCTCTGAGC
	S394E (reverse)	GCTCAGAGGATGGCTATTCTCGATGTGCAGATCCACGG
IRF3-2E	S396E (forward)	GGATCTGCACATCGAGAATGAACATCCTCTGAGCCTGACG
	S396E (reverse)	CGTCAGGCTCAGAGGATGTTTCATTCTCGATGTGCAGATCC
IRF3-3E	S400E (forward)	CGAGAATGAACATCCTCTGGAACCTGACGAGCGACCAGTAC
	S400E (reverse)	GTACTGGTTCGCTCGTCAGTTCAGAGGATGTTTCATTCTCG
IRF3-5E	T402E/S403E (forward)	GAATGAACATCCTCTGGAACCTGGAAGAAGACCAGTACAAGGCGTGTCTGC
	T402E/S403E (reverse)	GCAGACACGCCTTGACTGGTCTTCTCCAGTTCAGAGGATGTTTCATTCTCG
IRF3-5E/E	S384E (forward)	CACGTGACGGTGGTGAAGCGAATTGGAGAATACCGTGGATCTG
	S384E (reverse)	CAGATCCACGGTATTCTCCAATTCGCTTGACCACCGTACCGTG

^a Full-length IRF3 was used as the template for the first reaction to mutate Ser394 to Glu (IRF3-1E). Subsequent Glu substitutions were made using the product from the previous mutagenesis as the template.

proteins were expressed with an N-terminal 6×His tag. The nucleotide sequence of the gene was optimized for expression in *Escherichia coli*. The individual domains of IRF3 were designed on the basis of the sequence alignment between the human and porcine IRF3 proteins, which share a sequence identity of 78%. The DNA-binding domain of porcine IRF3 (IRF3-DBD) spans amino acids 1 to 114. Site-directed mutagenesis with the primer pair 5'-GCGTCGGTGACTTCTAACCTGAGCCAGACACC-3' (forward) and 5'-GGTGTCTGGCTCAGGTTAGAAAGTCACC GACGC-3' (reverse) was used to insert a stop codon in the wild-type IRF3 gene to generate the IRF3-DBD expression plasmid. The C-terminal domain of IRF3 (IRF3-IAD) containing the autoinhibitory region and the serine-rich region spans amino acids 171 to 419. IRF3-IAD was subcloned from full-length porcine IRF3 using the primer pair 5'-GCACATATGTC CCCGAGCGTGGACGCACCGGC-3' (forward) and 5'-GCACTCGAGT CATTAGAAGTCCATATCTTCCACCAGGTCGCGC-3' (reverse). The phosphomimetic glutamic acid mutant (IRF3-5E/E) was generated using sequential site-directed mutagenesis on the wild-type pJ414-IRF3 plasmid. Site I amino acid S384 and site II amino acids S394, S396, S400, T402, and S403 were all mutated to glutamic acid. A complete list of the primers used for the site-directed mutagenesis reactions of IRF3-5E/E is given in Table 1. DNA encoding the 46-amino-acid domain of CBP (residues 2065 to 2111), previously identified to be the interferon response binding domain, was synthesized and cloned into pJ411 (DNA2.0) carrying the T7 polymerase promoter and a kanamycin resistance cassette. The final construct has additional two residues (Met and Ser) at the N terminus and is thus named CBP₄₈. The C-terminal deletion mutant of IRF3, IRF3-ΔC, which lacks the terminal autoinhibitory region (amino acids 392 to 419), was generated from the full-length protein using site-directed mutagenesis to insert a stop codon after Leu391 with the primer pair 5'-GAATACCGTGGATCTGCACTAATCAGCAATAGCCATC CTC-3' (forward) and 5'-GAGGATGGCTATTGCTGATTAGTGCAG ATCCACGGTATTCT-3' (reverse). All plasmid constructs were verified by DNA sequencing at the University of Texas Medical Branch's molecular genomics core.

Expression and purification of N^{Pro} and IRF3 proteins. Recombinant IRF3 proteins were expressed in *E. coli* BL21(DE3) cells (Stratagene) grown in Terrific broth supplemented with 50 μg/ml of ampicillin. Cells were grown at 37°C to an optical density at 600 nm of 0.8, and protein expression was induced by the addition of 0.5 mM IPTG (isopropyl-β-D-thiogalactopyranoside), with growth being continued overnight at 18°C. The cell pellet from a 2-liter culture was resuspended in 50 ml of lysis buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl) and lysed by sonication. Protein in the soluble fraction of the lysate was loaded onto Talon (Clontech) metal-affinity chromatography resin preequilibrated in lysis buffer. Bound IRF3 was eluted using a gradient of 5 to 150 mM

imidazole in wash buffer (50 mM sodium phosphate, pH 7.1, 300 mM NaCl). Fractions containing IRF3 were pooled and concentrated to a final volume of 1 ml using an Amicon Ultra centrifugal filter device (Millipore). The sample was then loaded onto a Superdex 200 size exclusion column (GE Healthcare) that had been preequilibrated with buffer A (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM β-mercaptoethanol) in order to separate IRF3 from degradation products. Following size exclusion chromatography (SEC), the protein was further purified using anion-exchange chromatography. Pooled protein from size exclusion chromatography was exchanged into buffer B (20 mM Tris-HCl, pH 7.5, 50 mM NaCl) and loaded onto MonoQ anion-exchange column (GE Healthcare) equilibrated in buffer B. A salt gradient from 50 mM to 400 mM NaCl was used to elute pure IRF3 from the column. IRF3-DBD and IRF3-IAD were similarly purified but without the anion-exchange chromatography step.

To express IRF3-5E/E and CBP₄₈ together, the IRF3-5E/E- and CBP₄₈-expressing plasmids were cotransformed into *E. coli* BL21 (DE3) cells, and the transformants were selected for dual antibiotic resistance to ampicillin and kanamycin. The two proteins were then coexpressed under conditions similar to those used for wild-type IRF3 expression. IRF3-5E/E and CBP₄₈ were then coextracted from the cell lysate using metal-affinity chromatography on Talon resin. IRF3-5E/E and CBP₄₈ formed a tight complex that was further purified from the degradation products and low-molecular-mass contaminants using size exclusion chromatography in buffer A. The IRF3-5E/E-CBP₄₈ complex was buffer exchanged into 20 mM Tris, pH 7.5, and 100 mM NaCl and subjected to anion-exchange chromatography on the MonoQ column. A gradient between 100 mM and 1 M NaCl was used to elute the pure complex from the column. Similarly, the IRF3-ΔC-CBP₄₈ protein complex was purified using Talon metal affinity chromatography followed by size exclusion chromatography on Superdex 200. Full-length CSFV N^{Pro} and the N-terminal deletion mutant of CSFV N^{Pro} that lacked the first 17 amino acids (the Δ17N mutant) were expressed and purified as previously described (32, 34). SDS-polyacrylamide gel electrophoresis (PAGE) analysis showed that the purified proteins were greater than 95% pure.

Gel shift assay. Binding of N^{Pro} to full-length IRF3 and individual IRF3 domains (DBD and IAD) was tested by native PAGE using a GE PhastGel mini-electrophoresis system (GE Healthcare Life Sciences). Native PAGE was run using precast gradient gels, either 4 to 15% or 10 to 15%, following the manufacturer's recommendations. PhastGel native buffer strips were used to maintain the buffer composition during electrophoresis at 0.88 M L-alanine and 0.25 M Tris, pH 8.8. Prior to electrophoresis all protein samples were prepared in 20 mM Tris buffer at pH 7.5 and 200 mM NaCl. IRF3 constructs were either incubated with N^{Pro} or diluted to the same volume with buffer before loading on the gel. Native-Mark, a colored native gel protein marker from Invitrogen, was used as a

reference for the electrophoresis run. To extract proteins, native PAGE analysis was repeated using Mini-Protean TGX precast gels from Bio-Rad. Following electrophoresis, the gels were stained using colloidal Coomassie G-250 in water, and the individual protein bands were excised. Proteins were eluted into 20 μ l of 20 mM Tris buffer, pH 7.5, containing 200 mM NaCl and loaded onto SDS-containing polyacrylamide gels for identification.

Size exclusion chromatography of N^{PtO}-IRF3 complexes. Purified N^{PtO} and IRF3 proteins (full-length IRF3, the IRF3-5E/E-CBP₄₈ complex, the IRF3- Δ C-CBP₄₈ complex, and IRF3-DBD) were mixed and loaded onto a Superdex 200 size exclusion chromatography column (GE Healthcare Life Sciences) preequilibrated in buffer A. IRF3-IAD was incubated with N^{PtO} and loaded onto a Superdex 75 size exclusion chromatography column. A light precipitate was visible in the IRF3-IAD and N^{PtO} mixture and removed by centrifugation prior to application of the mixture to the column. Protein peaks on the chromatogram were analyzed by SDS-PAGE to verify coelution and, by extension, complex formation in the protein mixtures.

Analytical ultracentrifugation of the N^{PtO}-IRF3 complex. IRF3 and the mixture of N^{PtO} and IRF3 were analyzed by sedimentation velocity using a Beckman Coulter XL-A analytical ultracentrifuge. Following buffer exchange against buffer A, the protein solution was diluted with the buffer to yield an absorbance at 280 nm of 0.3. A 400- μ l aliquot was loaded into the sample compartment of a double-sector cell, assembled with 1.2-cm charcoal-Epon centerpiece and quartz windows. Dialysis buffer was placed in the reference compartment. The protein samples were sedimented at 45,000 rpm at 20°C. A total of 400 scans were collected. The resulting data set was analyzed with SEDFIT software, version 9.4, using the *c(s)* continuous size distribution model, allowing the frictional ratio to float (36).

RESULTS

CSFV N^{PtO} binds to the IRF3 monomer directly and forms a 1:1 complex in solution. Immunoprecipitation, coimmunofluorescence, and mammalian two-hybrid assays have all indicated that wild-type pestivirus N^{PtO} interacts with IRF3 *in vivo* (26, 30). This interaction is responsible for the subsequent ubiquitination and degradation of IRF3 by the proteasome. IRF3 undergoes multiple conformational changes during activation, but it is not known to which species of IRF3 N^{PtO} binds, inducing the proteasomal degradation of IRF3. In the mammalian two-hybrid assay used to show the interaction between N^{PtO} and IRF3, the IRF3 protein pulled down with N^{PtO} is likely to be a monomer, since IRF3 is expressed from a plasmid and is not activated. These assays, however, do not show whether N^{PtO} and IRF3 interact directly without additional proteins. We thus used recombinant N^{PtO} and IRF3 proteins to test if they interact directly *in vitro* using a native gel shift assay and size exclusion chromatography (SEC). To this end, we expressed recombinant CSFV N^{PtO} and porcine IRF3 in bacteria. Full-length N^{PtO} and the N-terminal deletion mutant lacking the first 17 amino acids (the Δ 17N mutant) were used to test their interaction with IRF3. The Δ 17N construct, whose high-resolution crystal structure was determined previously (34), was chosen because it is less prone to degradation than the full-length protein. Full-length and Δ 17N N^{PtO} have been shown to be functionally identical with respect to their protease and interferon antagonistic activities (20, 30, 34). Native gel shift assays showed that in the presence of either full-length or Δ 17N N^{PtO}, the IRF3 protein band shifted to a higher molecular mass (Fig. 1B, left). N^{PtO} is a highly basic protein and hence migrated in the opposite direction, toward the cathode (see Fig. 4A, left). In order to verify that the higher-molecular-mass product seen in the gel shift assay corresponds to the N^{PtO}-IRF3 protein complex, the higher-molecular-

mass bands were excised and proteins were eluted from the gel. The eluted proteins were then analyzed by denaturing SDS-PAGE. SDS-PAGE showed the presence of both IRF3 and the respective N^{PtO} proteins (Fig. 1B, right). The result indicates that N^{PtO} and IRF3 interact directly and the first 17 amino acids of N^{PtO} are not required for this interaction. Because of the superior stability of Δ 17N N^{PtO}, further studies on the interaction of N^{PtO} with IRF3 were carried out using this shorter construct.

We further analyzed the formation of the N^{PtO} and IRF3 complex using SEC. The individual N^{PtO} and IRF3 proteins eluted as monomers, as determined by SEC. When the mixture of N^{PtO} and IRF3 at a 2:1 molar ratio was loaded onto the SEC column, two major peaks were observed (Fig. 1C, left). Peak 1 contained both N^{PtO} (17 kDa) and IRF3 (49 kDa) proteins, as identified by SDS-PAGE (Fig. 1C, right). Thus, N^{PtO} and IRF3 interact directly and form a stable complex in solution, consistent with the native PAGE result. Excess free N^{PtO} was seen in the later lower-molecular-mass peak (peak 2).

The stoichiometry of N^{PtO} and IRF3 in the N^{PtO}-IRF3 complex was next determined using analytical ultracentrifugation (Fig. 1D). IRF3 alone or as a mixture with N^{PtO} was subjected to sedimentation velocity experiments. Consistent with the SEC result, IRF3 alone was a monomer in its native form with a sedimentation coefficient of 3.1S, corresponding to a molecular mass of 42 kDa. The calculated molecular mass of IRF3 is 49 kDa. The N^{PtO} and IRF3 mixture (1.5:1 ratio) shows two species at 1.7S and 3.8S, which correspond to the predicted molecular masses of 19 and 57 kDa, respectively (Fig. 1D). The 19-kDa peak would correspond to the N^{PtO} monomer, and the 57-kDa peak would correspond to the N^{PtO}-IRF3 complex; the calculated molecular masses of N^{PtO} and the N^{PtO}-IRF3 complex are 17 and 66 kDa, respectively. Thus, N^{PtO} and IRF3 form a 1:1 complex in solution.

Full-length IRF3 is required for stable interaction with N^{PtO}. IRF3 consists of two domains, the N-terminal DNA-binding domain (DBD) and the C-terminal IRF association domain (IAD) (Fig. 1A). To localize the region of IRF3 required for interaction with N^{PtO}, we designed constructs expressing the two IRF3 domains, IRF3-DBD (residues 1 to 114) and IRF3-IAD (residues 171 to 419), separately. Binding between N^{PtO} and each IRF3 domain was tested using a gel shift assay and SEC. IRF3-DBD runs as a mixture of species seen as a smear on a native gel (Fig. 2A). Addition of N^{PtO} to IRF3-DBD did not result in a shift of IRF3-DBD, indicating that the two proteins did not interact *in vitro* (Fig. 2A). SEC was also used to determine the interaction between N^{PtO} and IRF3-DBD. Because of the similarity in the sizes of N^{PtO} (17 kDa) and IRF3-DBD (15 kDa), the elution profile of N^{PtO} and the IRF3-DBD protein mixture showed one broad peak (Fig. 2B). However, SDS-PAGE showed two different concentration profiles corresponding to the two proteins in the peak, suggesting that the proteins did not interact with each other (Fig. 2B). Coelution resulting from stable complex formation would have resulted in a concomitant increase or decrease in their concentrations during elution. Thus, the results of both the native gel shift assay and SEC indicate that N^{PtO} does not interact with IRF3-DBD.

IRF3-IAD (25 kDa) mediates the homo- and heterodimeric interactions of IRF3 and binding to its transcriptional cofactors (11, 12) (Fig. 1A). On the native gel, IRF3-IAD showed a single band. Addition of N^{PtO} to IRF3-IAD (at a 1:1 or 2:1 ratio) did not induce any shift in the IRF3-IAD protein band (Fig. 2C), suggesting that N^{PtO} did not form a complex with IRF3-IAD. When SEC




FIG 2 N^{Pto} does not interact with individual domains of IRF3. (A) Gel shift assays of the DNA-binding domain of IRF3 (IRF3-DBD) in the presence of N^{Pto}. Left lane, IRF3-DBD alone; right lane, IRF3-DBD mixed with N^{Pto}. Note the lack of a shift in the position of IRF3-DBD in the presence of N^{Pto}. (B) (Left) Elution profile from SEC of an IRF3-DBD and N^{Pto} solution on a Superdex 200 column. (Right) SDS-PAGE of the fractions from the elution peak on the chromatogram. Bands corresponding to IRF3-DBD and N^{Pto} are indicated. (C) Gel shift assays of the IRF association domain (IRF3-IAD) in the presence of N^{Pto}. Left lane, IRF3-IAD; right lane, IRF3-IAD mixed with N^{Pto}. (D) (Left) Elution profile from SEC of an IRF3-IAD and N^{Pto} solution on a Superdex 75 column. (Right) SDS-PAGE of the fractions from the two elution peaks. Positions of IRF3-IAD and N^{Pto} in the gel are indicated. The numbers to the right of the gels are molecular masses (in kilodaltons).

was used to determine the interaction, however, a small amount of N^{Pto} coeluted with IRF3-IAD (Fig. 2D, right). SDS-PAGE analysis of the higher-molecular-mass peak (peak 1) showed that IRF3-IAD was present at a much higher concentration than N^{Pto} in the coeluted fractions and the majority of N^{Pto} eluted in a separate lower-molecular-mass peak (peak 2). Although the SEC result suggests a weak interaction between N^{Pto} and IRF3-IAD, when the results were taken together with the results of the gel shift assay, we concluded that IRF3-IAD is not sufficient to form a stable complex with N^{Pto}.

N^{Pto} binds to the phosphomimetic IRF3-5E/E monomer and dimer in the presence of CBP. Phosphorylation of IRF3 in the cytoplasm leads to its activation and dimerization, following which it translocates into the nucleus. In the nucleus, the activated dimer of IRF3 associates with the CREB-binding protein (CBP), among other cofactors, to form the transcription complex that regulates the IFN- α/β gene promoters (4, 37). We thus tested whether N^{Pto} binds the phosphorylated IRF3 dimer using a phosphomimetic mutant, IRF3-5E/E. Phosphorylation of IRF3 occurs at two highly conserved Ser/Thr clusters, *viz.*, site I and site II, in the serine-rich region of IRF3 (Fig. 1A). Site I is constituted by S383 and S384, and site II is formed by S394, S396, S400, T402, and S403 (37–40). It was shown that the IRF3 phosphomimetic mutant, in which all five Ser/Thr residues at site II were replaced with Asp or Glu residues (IRF3-5D and IRF3-5E, respectively), forms a stable IRF3 dimer that constitutively binds DNA (10, 41, 42). In the case of IRF3-5D expressed in insect cells, an additional phosphorylation in site I was observed, suggesting that the phosphor-

ylation at site I may also be important for IRF3 activation (41). We thus generated IRF3-5E/E, in which all five Ser/Thr residues in site II were mutated to Glu (S394E, S396E, S400E, T402E, and S403E) with an additional S384E substitution at site I. Because S385 in human IRF3 was reported to have an autoinhibitory function rather than an activating function (38), the corresponding S383 in porcine IRF3 was not changed to Glu. IRF3-5E/E was found to be both a monomer and a dimer in solution, but the construct was unstable and degraded rather rapidly. To stabilize the IRF3 dimer, we coexpressed a CBP peptide along with IRF3-5E/E. Although CBP is a large ~250-kDa protein, its interaction with IRF3 is mediated by the small interferon response binding domain (IBiD; 46 residues) (43). The binding of IBiD to the phosphomimetic mutants of IRF3 has been shown to induce the dimerization of IRF3 in solution (38). Thus, a 48-amino-acid domain of CBP (referred to here as CBP₄₈) was used for coexpression. CBP binds to both the monomeric and dimeric 5E/E forms of IRF3. Accordingly, IRF3-5E/E–CBP₄₈ complexes eluted as two peaks in SEC. The peak with the higher molecular mass is likely the heterotetramer of the IRF3-5E/E dimer and two CBP₄₈ proteins, and the peak with the lower molecular mass is the heterodimer of the IRF3-5E/E monomer and CBP₄₈ (Fig. 3).

With IRF3-5E/E–CBP₄₈ we tested whether the phosphomimetic IRF3 mutant interacts with N^{Pto} using a gel shift assay. In the presence of N^{Pto}, both the activated monomer and dimer species of IRF3 were shifted toward a higher molecular mass in the native gel (Fig. 3A). This clearly indicates that N^{Pto} binds the constitutively active form of IRF3 even in the presence of its cofactor, CBP.




FIG 3 N^{pro} interacts with the IRF3-5E/E-CBP₄₈ complex. (A) Gel shift assay of IRF3-5E/E-CBP₄₈ in the presence of N^{pro}. Left lane, IRF3-5E/E-CBP₄₈ complex; right lane, IRF3-5E/E-CBP₄₈ complex mixed with N^{pro}. Phosphomimetic mutant IRF3-5E/E and CBP₄₈ form a heterotetramer (IRF3-5E/E dimer and two CBP₄₈ proteins) and a heterodimer (IRF3-5E/E monomer and one CBP₄₈ protein) (left lane), and N^{pro} interacts with both IRF3-5E/E-CBP₄₈ forms (right lane). Arrows, positions of monomeric and dimeric IRF3-5E/E bound to CBP₄₈ and their N^{pro} complexes. (B) (Left) Elution profile from SEC of IRF3-5E/E-CBP₄₈ and N^{pro} solution on a Superdex 200 column. (Right) SDS-PAGE of the peak fractions shows that both the CBP₄₈-bound monomer and the CBP₄₈-bound dimer of IRF3-5E/E coelute with N^{pro}. Excess unbound N^{pro} eluted in the third peak. The numbers to the right of the gel are molecular masses (in kilodaltons).

Next, IRF3-5E/E-CBP₄₈ and N^{pro} were mixed and separated by SEC. The SEC profile showed three peaks (Fig. 3B, left). Even though distinct peaks were observed for the IRF3-5E/E-CBP₄₈ heterodimer and heterotetramer, SEC could not resolve the free IRF3-5E/E-CBP₄₈ and the complexed IRF3-5E/E-CBP₄₈-N^{pro} species. SDS-PAGE analysis identified that the first two peaks (peaks 1 and 2) contained N^{pro}, IRF3-5E/E, and CBP₄₈, confirming that N^{pro} interacts with both the IRF3-5E/E monomer and the IRF3-5E/E dimer in the presence of CBP. Thus, N^{pro} and CBP do not appear to compete for IRF3 binding, indicating that the N^{pro}-binding site on IRF3 and the CBP-binding site on IRF3-IAD are two distinct sites.

The C-terminal autoinhibitory region of IRF3 is not required for interaction with N^{pro}. Since N^{pro} binds to the IRF3 monomer and phosphomimetic IRF3-5E/E monomer and dimer, N^{pro} likely recognizes the structural features that are shared in both the IRF3 monomer and dimer. Phosphorylation of IRF3 results in the release of the C-terminal autoinhibitory region, exposing the dimerization interface and the cofactor (here, CBP) binding region on IRF3. Since phosphorylation, dimerization, and subsequent CBP binding could involve major rearrangements in the autoinhibitory region at the C terminus (9, 13), this region is not likely responsible for the physical interaction of IRF3 with N^{pro}. We thus tested whether the C-terminal autoinhibitory region of IRF3 is required for the interaction of IRF3 with N^{pro}. To this end we constructed a C-terminal deletion mutant, IRF3-ΔC, that lacks 27 amino acids at the C terminus, including the second phosphorylation site, site II (residues 392 to 419) (Fig. 1A). Because the C-terminal deletion in IRF3-ΔC would expose the CBP-binding site, we coexpressed IRF3-ΔC with CBP₄₈. IRF3-ΔC indeed formed a complex with CBP₄₈ that could be purified using SEC. In the native gel shift assay, the mixture of the purified IRF3-ΔC-CBP₄₈ complex and N^{pro} was predominantly localized in the well and remained immobile (Fig. 4A, left). In order to determine the composition of the immobile product in the native gel, proteins were eluted from the band and loaded onto SDS-polyacrylamide gels. The product contained IRF3-ΔC, CBP₄₈, and N^{pro} proteins (Fig. 4A, right). Thus, N^{pro} binds to the IRF3-ΔC-CBP₄₈ complex in solution. The IRF3-ΔC-CBP₄₈ complex was also mixed with N^{pro} and loaded onto an SEC column. All three proteins, N^{pro}, IRF3-ΔC, and CBP₄₈, coeluted as a single peak, as shown by the chromatogram and SDS-PAGE analysis (Fig. 4B). This indicates that the C-terminal 27 residues that contain phosphorylation site

II or the CBP-binding site on IRF3 are not involved in N^{pro} binding. Thus, N^{pro} recognizes the structural features of IRF3 that do not undergo a conformational change during IRF3 activation and dimerization, in line with our results showing that N^{pro} is able to recognize both the IRF3 monomer and the IRF3 dimer.

DISCUSSION

We have shown that N^{pro} forms a stable soluble complex with wild-type full-length IRF3 *in vitro*. This is the first report that conclusively demonstrates a direct one-to-one interaction between the two proteins in solution. We further show that N^{pro} cannot form a complex with the individual domains of IRF3, the




FIG 4 N^{pro} interacts with the IRF3-ΔC-CBP₄₈ complex. (A) (Left) Gel shift assay of the IRF3-ΔC-CBP₄₈ complex in the presence of N^{pro}. IRF3-ΔC-CBP₄₈, N^{pro}, and the mixture of IRF3-ΔC-CBP₄₈ and N^{pro} were loaded onto a native polyacrylamide gel. The immobile band indicated by an asterisk was eluted for SDS-PAGE analysis (right). Note that N^{pro} migrates in the opposite direction from the loading position, toward the cathode. (Right) SDS-PAGE of the N^{pro} and IRF3-ΔC-CBP₄₈ complex (lane 1) along with IRF3-ΔC-CBP₄₈ and N^{pro} (lanes 2 and 3, respectively) is shown. (B) (Left) Elution profile from SEC of IRF3-ΔC-CBP₄₈ and N^{pro} on a Superdex 200 column. (Right) SDS-PAGE shows that N^{pro} coelutes with the IRF3-ΔC-CBP₄₈ complex in peak 1. The numbers to the right of the gels are molecular masses (in kilodaltons).

N-terminal DBD or the C-terminal IAD; thus, the N^{PRO}-IRF3 interaction requires both IRF3 domains. Previously, a mammalian two-hybrid assay was used to show that N^{PRO}'s interaction with IRF3 requires both the DBD and the IAD of IRF3 (28). Either the DBD or the IAD alone had only 5 to 10% of the N^{PRO}-binding ability compared to that of full-length IRF3. The largest IRF3 construct tested, consisting of residues 1 to 272 containing the DBD and partial IAD of IRF3, had ~20% of the N^{PRO}-binding ability of full-length IRF3 (28). The findings of the present *in vitro* interaction studies using the recombinant proteins are consistent with those of the mammalian two-hybrid assay. Additionally, we have shown that N^{PRO} interacts with IRF3-ΔC, which lacks the C-terminal 27 amino acids, and thus, the C-terminal phosphorylation site in IRF3 is not required for N^{PRO} binding. Furthermore, the binding interaction between N^{PRO} and IRF3 is independent of IRF3's activation state, and N^{PRO} is able to form a complex with the inactive IRF3 monomer as well as the constitutively active monomer and dimer (IRF3-5E/E). Thus, N^{PRO} likely induces the degradation of the inactive IRF3 monomer and the activated phosphorylated IRF3 dimer in the cytoplasm. Finally, the presence of CBP, a co-factor of IRF3, does not interfere with its interaction with N^{PRO} *in vitro*. These data support the findings of previous *in vivo* studies that N^{PRO} does not disrupt activation of IRF3 or its translocation into the nucleus (26).

The N^{PRO}-binding site on IRF3 is currently unknown. Since N^{PRO} does not recognize the individual IRF3 domains, it is likely that the N^{PRO}-binding site on IRF3 is composed of the two IRF3 domains, including the ~60-amino-acid linker region in between (Fig. 1A). However, the full-length IRF3 structure is unavailable, and it is therefore not known how the DBD and the IAD are arranged in the IRF3 monomer and dimer (11, 44, 45). The linker region is shown to be partially helical in the full-length IRF3 protein, while it is not structured when either of the domains is absent (46). Thus, the intact linker region may also be involved in N^{PRO} binding. N^{PRO} interacts with the IRF3 monomer and phosphomimetic dimer, suggesting that N^{PRO} recognizes a structural feature of IRF3 that is preserved during IRF3 activation from a monomer to a dimer. Since the C-terminal phosphorylation sites on IRF3 undergo significant structural changes and expose the CBP-binding site during IRF3 activation, N^{PRO} is unlikely to recognize the phosphorylation sites or the CBP-binding site for interaction. Indeed, N^{PRO} interacts with IRF3-ΔC in complex with CBP, indicating that the C-terminal phosphorylation sites or the CBP-binding site of IRF3 is not involved in N^{PRO} interaction.

CSFV N^{PRO} interacts with the phosphomimetic IRF3 dimer and CBP-bound form of IRF3, the predominant forms in the nucleus. Since N^{PRO}'s function of degrading IRF3 has been shown only in the cytoplasm, N^{PRO} is likely to induce the degradation of the IRF3 dimer by the proteasome when the IRF3 dimer is formed or exported from the nucleus. It is currently not clear whether N^{PRO} has an additional role in the nucleus. N^{PRO} is shown to diffuse into the nucleus (47, 48), wherein it would interact with the IRF3 dimer or the CBP-bound form of the IRF3 dimer. In the nucleus, the IRF3 dimer binds to the transcriptional coactivator CBP and subsequently to the promoter region of beta interferon genes to activate transcription of interferon genes. Interaction of N^{PRO} with IRF3 in the nucleus could thus interfere with its role as a transcription factor, facilitating viral replication further. BVDV N^{PRO} has been shown to inhibit IRF3 from binding to DNA even when the proteasomal degradation of IRF3 is blocked (27). Whether CSFV N^{PRO}

also inhibits the transcriptional activity of IRF3 in the nucleus is not known and requires further investigation.

FUNDING INFORMATION

This work, including the efforts of Nicolas Ruggli, was funded by Swiss National Science Foundation (31003A-116608 and 310030-141045). This work, including the efforts of Kyung H. Choi, was funded by National Institute of Food and Agriculture (NIFA) (AFRI 2015-67015-23132).

REFERENCES

- Kawai T, Akira S. 2006. Innate immune recognition of viral infection. *Nat Immunol* 7:131–137. <http://dx.doi.org/10.1038/ni1303>.
- Fensterl V, Sen GC. 2009. Interferons and viral infections. *Biofactors* 35:14–20. <http://dx.doi.org/10.1002/biof.6>.
- Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. *Nat Rev Immunol* 6:644–658. <http://dx.doi.org/10.1038/nri1900>.
- Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. *Immunity* 25:349–360. <http://dx.doi.org/10.1016/j.immuni.2006.08.009>.
- Tamura T, Yanai H, Savitsky D, Taniguchi T. 2008. The IRF family transcription factors in immunity and oncogenesis. *Annu Rev Immunol* 26:535–584. <http://dx.doi.org/10.1146/annurev.immunol.26.021607.090400>.
- Haller O, Kochs G, Weber F. 2006. The interferon response circuit: induction and suppression by pathogenic viruses. *Virology* 344:119–130. <http://dx.doi.org/10.1016/j.virol.2005.09.024>.
- Takeuchi O, Akira S. 2009. Innate immunity to virus infection. *Immunol Rev* 227:75–86. <http://dx.doi.org/10.1111/j.1600-065X.2008.00737.x>.
- Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. 2011. Pattern recognition receptors and the innate immune response to viral infection. *Viruses* 3:920–940. <http://dx.doi.org/10.3390/v3060920>.
- Chen W, Royer WE, Jr. 2010. Structural insights into interferon regulatory factor activation. *Cell Signal* 22:883–887. <http://dx.doi.org/10.1016/j.cellsig.2009.12.005>.
- Lin R, Mamane Y, Hiscott J. 1999. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. *Mol Cell Biol* 19:2465–2474. <http://dx.doi.org/10.1128/MCB.19.4.2465>.
- Qin BY, Liu C, Lam SS, Srinath H, Delston R, Correia JJ, Derynck R, Lin K. 2003. Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. *Nat Struct Biol* 10:913–921. <http://dx.doi.org/10.1038/nsb1002>.
- Qin BY, Liu C, Srinath H, Lam SS, Correia JJ, Derynck R, Lin K. 2005. Crystal structure of IRF-3 in complex with CBP. *Structure* 13:1269–1277. <http://dx.doi.org/10.1016/j.str.2005.06.011>.
- Chen W, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, Fitzgerald KA, Lin K, Royer WE, Jr. 2008. Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. *Nat Struct Mol Biol* 15:1213–1220. <http://dx.doi.org/10.1038/nsmb.1496>.
- Lin R, Genin P, Mamane Y, Hiscott J. 2000. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. *Mol Cell Biol* 20:6342–6353. <http://dx.doi.org/10.1128/MCB.20.17.6342-6353.2000>.
- Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. *Science* 327:291–295. <http://dx.doi.org/10.1126/science.1183021>.
- Summerfield A, Ruggli N. 2015. Immune responses against classical swine fever virus: between ignorance and lunacy. *Front Vet Sci* 2:10. <http://dx.doi.org/10.3389/fvets.2015.00010>.
- Magkouras I, Mätzner P, Rümenapf T, Peterhans E, Schweizer M. 2008. RNase-dependent inhibition of extracellular, but not intracellular, dsRNA-induced interferon synthesis by Erns of pestiviruses. *J Gen Virol* 89:2501–2506. <http://dx.doi.org/10.1099/vir.0.2008/003749-0>.
- Mätzner P, Magkouras I, Rümenapf T, Peterhans E, Schweizer M. 2009. The viral RNase E(rns) prevents IFN type-I triggering by pestiviral single- and double-stranded RNAs. *Virus Res* 140:15–23. <http://dx.doi.org/10.1016/j.virusres.2008.10.015>.
- Iqbal M, Poole E, Goodbourn S, McCauley JW. 2004. Role for bovine viral diarrhoea virus Erns glycoprotein in the control of activation of beta

- interferon by double-stranded RNA. *J Virol* 78:136–145. <http://dx.doi.org/10.1128/JVI.78.1.136-145.2004>.
20. Zürcher C, Sauter KS, Mathys V, Wyss F, Schweizer M. 2014. Prolonged activity of the pestiviral RNase Erns as an interferon antagonist after uptake by clathrin-mediated endocytosis. *J Virol* 88:7235–7243. <http://dx.doi.org/10.1128/JVI.00672-14>.
 21. Python S, Gerber M, Suter R, Ruggli N, Summerfield A. 2013. Efficient sensing of infected cells in absence of virus particles by plasmacytoid dendritic cells is blocked by the viral ribonuclease E(rns.). *PLoS Pathog* 9:e1003412. <http://dx.doi.org/10.1371/journal.ppat.1003412>.
 22. Rumenapf T, Stark R, Heimann M, Thiel HJ. 1998. N-terminal protease of pestiviruses: identification of putative catalytic residues by site-directed mutagenesis. *J Virol* 72:2544–2547.
 23. Gottipati K, Acholi S, Ruggli N, Choi KH. 2014. Autocatalytic activity and substrate specificity of the pestivirus N-terminal protease N(pro). *Virology* 452–453:303–309. <http://dx.doi.org/10.1016/j.virol.2014.01.026>.
 24. Seago J, Hilton L, Reid E, Doceul V, Jeyatheesan J, Moganeradj K, McCauley J, Charleston B, Goodbourn S. 2007. The Npro product of classical swine fever virus and bovine viral diarrhoea virus uses a conserved mechanism to target interferon regulatory factor-3. *J Gen Virol* 88:3002–3006. <http://dx.doi.org/10.1099/vir.0.82934-0>.
 25. Chen Z, Rijnbrand R, Jangra RK, Devaraj SG, Qu L, Ma Y, Lemon SM, Li K. 2007. Ubiquitination and proteasomal degradation of interferon regulatory factor-3 induced by Npro from a cytopathic bovine viral diarrhoea virus. *Virology* 366:277–292. <http://dx.doi.org/10.1016/j.virol.2007.04.023>.
 26. Bauhofer O, Summerfield A, Sakoda Y, Tratschin JD, Hofmann MA, Ruggli N. 2007. Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. *J Virol* 81:3087–3096. <http://dx.doi.org/10.1128/JVI.02032-06>.
 27. Hilton L, Moganeradj K, Zhang G, Chen YH, Randall RE, McCauley JW, Goodbourn S. 2006. The NPro product of bovine viral diarrhoea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. *J Virol* 80:11723–11732. <http://dx.doi.org/10.1128/JVI.01145-06>.
 28. Fiebach AR, Guzylack-Piriou L, Python S, Summerfield A, Ruggli N. 2011. Classical swine fever virus N(pro) limits type I interferon induction in plasmacytoid dendritic cells by interacting with interferon regulatory factor 7. *J Virol* 85:8002–8011. <http://dx.doi.org/10.1128/JVI.00330-11>.
 29. Tamura T, Nagashima N, Ruggli N, Summerfield A, Kida H, Sakoda Y. 2014. Npro of classical swine fever virus contributes to pathogenicity in pigs by preventing type I interferon induction at local replication sites. *Vet Res* 45:47. <http://dx.doi.org/10.1186/1297-9716-45-47>.
 30. Ruggli N, Summerfield A, Fiebach AR, Guzylack-Piriou L, Bauhofer O, Lamm CG, Waltersperger S, Matsuno K, Liu L, Gerber M, Choi KH, Hofmann MA, Sakoda Y, Tratschin JD. 2009. Classical swine fever virus can remain virulent after specific elimination of the interferon regulatory factor 3-degrading function of Npro. *J Virol* 83:817–829. <http://dx.doi.org/10.1128/JVI.01509-08>.
 31. Mayer D, Hofmann MA, Tratschin JD. 2004. Attenuation of classical swine fever virus by deletion of the viral N(pro) gene. *Vaccine* 22:317–328. <http://dx.doi.org/10.1016/j.vaccine.2003.08.006>.
 32. Szymanski MR, Fiebach AR, Tratschin JD, Gut M, Ramanujam VM, Gottipati K, Patel P, Ye M, Ruggli N, Choi KH. 2009. Zinc binding in pestivirus N(pro) is required for interferon regulatory factor 3 interaction and degradation. *J Mol Biol* 391:438–449. <http://dx.doi.org/10.1016/j.jmb.2009.06.040>.
 33. Kozasa T, Abe Y, Mitsuhashi K, Tamura T, Aoki H, Ishimaru M, Nakamura S, Okamatsu M, Kida H, Sakoda Y. 2015. Analysis of a pair of END+ and END– viruses derived from the same bovine viral diarrhoea virus stock reveals the amino acid determinants in Npro responsible for inhibition of type I interferon production. *J Vet Med Sci* 77:511–518. <http://dx.doi.org/10.1292/jvms.14-0420>.
 34. Gottipati K, Ruggli N, Gerber M, Tratschin JD, Benning M, Bellamy H, Choi KH. 2013. The structure of classical swine fever virus N(pro): a novel cysteine autoprotease and zinc-binding protein involved in subversion of type I interferon induction. *PLoS Pathog* 9:e1003704. <http://dx.doi.org/10.1371/journal.ppat.1003704>.
 35. Zogg T, Sponring M, Schindler S, Koll M, Schneider R, Brandstetter H, Auer B. 2013. Crystal structures of the viral protease Npro imply distinct roles for the catalytic water in catalysis. *Structure* 21:929–938. <http://dx.doi.org/10.1016/j.str.2013.04.003>.
 36. Schuck P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. *Biophys J* 78:1606–1619. [http://dx.doi.org/10.1016/S0006-3495\(00\)76713-0](http://dx.doi.org/10.1016/S0006-3495(00)76713-0).
 37. Lin R, Heylbroeck C, Pitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. *Mol Cell Biol* 18:2986–2996. <http://dx.doi.org/10.1128/MCB.18.5.2986>.
 38. Chen W, Srinath H, Lam SS, Schiffer CA, Royer WE, Jr, Lin K. 2008. Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 3. *J Mol Biol* 379:251–260. <http://dx.doi.org/10.1016/j.jmb.2008.03.050>.
 39. Mori M, Yoneyama M, Ito T, Takahashi K, Inagaki F, Fujita T. 2004. Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. *J Biol Chem* 279:9698–9702. <http://dx.doi.org/10.1074/jbc.M310612000>.
 40. Servant MJ, Grandvaux N, ten Oever BR, Duguay D, Lin R, Hiscott J. 2003. Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. *J Biol Chem* 278:9441–9447. <http://dx.doi.org/10.1074/jbc.M209851200>.
 41. Panne D, McWhirter SM, Maniatis T, Harrison SC. 2007. Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch. *J Biol Chem* 282:22816–22822. <http://dx.doi.org/10.1074/jbc.M703019200>.
 42. Dragan AI, Hargreaves VV, Makeyeva EN, Privalov PL. 2007. Mechanisms of activation of interferon regulator factor 3: the role of C-terminal domain phosphorylation in IRF-3 dimerization and DNA binding. *Nucleic Acids Res* 35:3525–3534. <http://dx.doi.org/10.1093/nar/gkm142>.
 43. Lin CH, Hare BJ, Wagner G, Harrison SC, Maniatis T, Fraenkel E. 2001. A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. *Mol Cell* 8:581–590. [http://dx.doi.org/10.1016/S1097-2765\(01\)00333-1](http://dx.doi.org/10.1016/S1097-2765(01)00333-1).
 44. Takahashi K, Suzuki NN, Horiuchi M, Mori M, Sahara W, Okabe Y, Fukuhara Y, Terasawa H, Akira S, Fujita T, Inagaki F. 2003. X-ray crystal structure of IRF-3 and its functional implications. *Nat Struct Biol* 10:922–927. <http://dx.doi.org/10.1038/nsb1001>.
 45. Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T. 1999. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. *EMBO J* 18:5028–5041. <http://dx.doi.org/10.1093/emboj/18.18.5028>.
 46. Shukla H, Vaitiekunas P, Majumdar AK, Dragan AI, Dimitriadis EK, Kotova S, Crane-Robinson C, Privalov PL. 2012. The linker of the interferon response factor 3 transcription factor is not unfolded. *Biochemistry* 51:6320–6327. <http://dx.doi.org/10.1021/bi300260s>.
 47. Doceul V, Charleston B, Crooke H, Reid E, Powell PP, Seago J. 2008. The Npro product of classical swine fever virus interacts with IkappaBalpha, the NF-kappaB inhibitor. *J Gen Virol* 89:1881–1889. <http://dx.doi.org/10.1099/vir.0.83643-0>.
 48. Li Y, Shen L, Li C, Huang J, Zhao B, Sun Y, Li S, Luo Y, Qiu HJ. 2014. Visualization of the Npro protein in living cells using biarsenically labeling tetracysteine-tagged classical swine fever virus. *Virus Res* 189:67–74. <http://dx.doi.org/10.1016/j.virusres.2014.04.018>.